Anika Therapeutics Valuation
ANIK Stock | USD 17.20 0.23 1.36% |
At this time, the firm appears to be undervalued. Anika Therapeutics shows a prevailing Real Value of $19.96 per share. The current price of the firm is $17.2. Our model approximates the value of Anika Therapeutics from analyzing the firm fundamentals such as Current Valuation of 213.7 M, return on equity of -0.43, and Profit Margin of (0.59) % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Anika Therapeutics' valuation include:
Price Book 1.3818 | Enterprise Value 213.7 M | Enterprise Value Ebitda (72.65) | Price Sales 1.5344 | Forward PE 19.1205 |
Undervalued
Today
Please note that Anika Therapeutics' price fluctuation is not too volatile at this time. Calculation of the real value of Anika Therapeutics is based on 3 months time horizon. Increasing Anika Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Anika Therapeutics' intrinsic value may or may not be the same as its current market price of 17.20, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. Historical | Market 17.2 | Real 19.96 | Target 26.33 | Hype 17.29 | Naive 19.99 |
The intrinsic value of Anika Therapeutics' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Anika Therapeutics' stock price.
Estimating the potential upside or downside of Anika Therapeutics helps investors to forecast how Anika stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Anika Therapeutics more accurately as focusing exclusively on Anika Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Anika Therapeutics' intrinsic value based on its ongoing forecasts of Anika Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Anika Therapeutics' closest peers.
Anika Therapeutics Cash |
|
Anika Valuation Trend
Knowing Anika Therapeutics' actual value is paramount for traders when making sound investment determinations. Using both Anika Therapeutics' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Anika Revenue by Product
Anika Therapeutics Total Value Analysis
Anika Therapeutics is presently forecasted to have valuation of 213.7 M with market capitalization of 251.9 M, debt of 29.04 M, and cash on hands of 87.78 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Anika Therapeutics fundamentals before making equity appraisal based on enterprise value of the companyTakeover Price | Market Cap | Debt Obligations | Cash |
213.7 M | 251.9 M | 29.04 M | 87.78 M |
Anika Therapeutics Investor Information
About 92.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.38. Some equities with similar Price to Book (P/B) outperform the market in the long run. Anika Therapeutics has Price/Earnings To Growth (PEG) ratio of 1.91. The entity recorded a loss per share of 6.73. The firm had not issued any dividends in recent years. Based on the key indicators related to Anika Therapeutics' liquidity, profitability, solvency, and operating efficiency, Anika Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December.Anika Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Anika Therapeutics has an asset utilization ratio of 61.58 percent. This suggests that the Company is making $0.62 for each dollar of assets. An increasing asset utilization means that Anika Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Anika Therapeutics Ownership Allocation
The market capitalization of Anika Therapeutics is $251.9 Million. The majority of Anika Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Anika Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Anika Therapeutics. Please pay attention to any change in the institutional holdings of Anika Therapeutics as this could imply that something significant has changed or is about to change at the company. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.Anika Therapeutics Profitability Analysis
The company reported the previous year's revenue of 166.66 M. Net Loss for the year was (82.67 M) with profit before overhead, payroll, taxes, and interest of 96.78 M.About Anika Therapeutics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Anika Therapeutics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Anika Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Anika Therapeutics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Anika Therapeutics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Anika Therapeutics. We calculate exposure to Anika Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Anika Therapeutics's related companies.Last Reported | Projected for Next Year | ||
Gross Profit | 103.1 M | 108.2 M | |
Pretax Profit Margin | (0.51) | (0.49) | |
Operating Profit Margin | (0.53) | (0.50) | |
Net Loss | (0.50) | (0.47) | |
Gross Profit Margin | 0.62 | 0.45 |
Anika Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Anika Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
Common Stock Shares Outstanding | 14.7 M | |
Quarterly Earnings Growth Y O Y | -0.505 | |
Forward Price Earnings | 19.1205 |
Anika Therapeutics Current Valuation Indicators
Anika Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Anika Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Anika Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Anika Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Anika Therapeutics' worth.When determining whether Anika Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Anika Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Anika Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Anika Therapeutics Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anika Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anika Therapeutics. If investors know Anika will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anika Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.51) | Earnings Share (6.73) | Revenue Per Share 11.139 | Quarterly Revenue Growth (0.07) | Return On Assets (0.04) |
The market value of Anika Therapeutics is measured differently than its book value, which is the value of Anika that is recorded on the company's balance sheet. Investors also form their own opinion of Anika Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Anika Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anika Therapeutics' market value can be influenced by many factors that don't directly affect Anika Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anika Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anika Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anika Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.